Navigation Links
ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Date:2/11/2011

EXTON, Pa., Feb. 11, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference at 2:40 P.M. ET on Thursday, February 17, 2011.  The conference is being held at the Roosevelt Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media s
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Participate in the 29th Annual J.P. Morgan Healthcare Conference
2. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
3. ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010
4. ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human])
5. ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data
6. ViroPharma to Participate in Two May Healthcare Investor Conferences
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma to Present at Four Additional Healthcare Conferences
9. ViroPharma to Present at Several Upcoming Healthcare Conferences
10. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
(Date:8/28/2014)... Vt. (PRWEB) August 28, 2014 ... testing around the world is available from Strategic ... diagnostics companies. “ Industrial Microbiology Market Review, Fourth ... Industrial Market ” (IMMR—4) tracks and compares microbiology ... in North America, Europe and Asia, and forecasts ...
(Date:8/28/2014)... 2014 Supplementing their complete line ... for Eppendorf Safe Lock Centrifuge Tubes . ... highest quality tubes at an affordable price. Eppendorf ... doing chemical, medical, pharmaceutical, and life science research ... regularly able to afford Eppendorf products. , Eppendorf ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... Mass. and SAN DIEGO, Calif., April 16 ,Boston ... Inc. (Nasdaq: CRYO ),today announced the signing ... will pay a cash purchase price of $1.35 ... acquisition follows a,development agreement, in place since June ...
... the 99th Annual Meeting of the American ... Association for Cancer Research (AACR) ... Inc.,("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing,in ... for the management of cancer, today announced,presentations of further ...
... Serono and its US,affiliate EMD Serono, Inc., both ... planned expansion of EMD Serono,s US presence with ... facility northwest,of Boston, Massachusetts. The company anticipates that ... in Massachusetts., The investment will support the ...
Cached Biology Technology:Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 2Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 3Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 5Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 6Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 2Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 3Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040 4EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts 2EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts 3EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts 4
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... American College of Sports Medicine,s Conference on Integrative ... Miami, Florida. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the American College ...
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
(Date:8/28/2014)... 25 million kilometres of new roads will be built ... into Earth,s last wildernesses, where they bring an influx ... Now, an ambitious study has created a ,global roadmap, ... to balance the competing demands of development and environmental ... layer that estimates that natural importance of ecosystems and ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Livermore National Laboratory physicist and his colleagues have found ... used in physics to help solve problems in biology. ... modeling to shed light on something known as epigenetic ... memory of some variable condition, such as quality of ...
... had been reckoned until today to be around 2,000 million ... fish, in other words, ones found at depths of between ... international team*, in which AZTI-Tecnalia researchers are participating and which ... has discovered that its abundance could be at least 10 ...
... by excessive and systemic reaction of the entire body ... The number of deaths by septic shock in intensive ... despite numerous large scale clinical trials. Scientists of VIB ... mouse study that a potential novel treatment for sepsis ...
Cached Biology News:New application of physics tools used in biology 2Researchers at UGent and VIB, discovered potential novel treatment against septic shock 2
...
cysteine and glycine-rich protein 2,...
... Antitumour agent and DNA-topoisomersae II inhibitor (IC50 = ... C 29 H 32 O 13 ... Store at: RT ... Solubility: Soluble to 100 ...
HSPBP1 Antibody...
Biology Products: